30-Day Readmission Rates and Associated Factors after an Acute Exacerbation of Chronic Obstructive Pulmonary Disease, a Single Center Experience

2021 ◽  
Author(s):  
Aylin Ozgen Alpaydin ◽  
◽  
Saliha Selin Ozuygur ◽  
Ceyda Sahan ◽  
Kemal Can Tertemiz ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Acute Exacerbation ◽  
Associated Factors ◽  
Chronic Obstructive ◽  
Single Center ◽  
Readmission Rates ◽  
Obstructive Pulmonary Disease ◽  
Single Center Experience

scholarly journals Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Influence of Social Factors in Determining Length of Hospital Stay and Readmission Rates

2008 ◽  
Vol 15 (7) ◽  
pp. 361-364 ◽  
Author(s):  
Alyson WM Wong ◽  
Wen Q Gan ◽  
Jane Burns ◽  
Don D Sin ◽  
Stephan F van Eeden
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Social Work ◽  
Marital Status ◽  
Pulmonary Disease ◽  
Acute Exacerbation ◽  
Social Factors ◽  
Chronic Obstructive ◽  
Readmission Rates ◽  
Obstructive Pulmonary Disease ◽  
Hospital Resources

BACKGROUND: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is the leading reason for hospitalization in Canada and a significant financial burden on hospital resources. Identifying factors that influence the time a patient spends in the hospital and readmission rates will allow for better use of scarce hospital resources.OBJECTIVES: To determine the factors that influence length of stay (LOS) in the hospital and readmission for patients with AECOPD in an inner-city hospital.METHODS: Using the Providence Health Records, a retrospective review of patients admitted to St Paul’s Hospital (Vancouver, British Columbia) during the winter of 2006 to 2007 (six months) with a diagnosis of AECOPD, was conducted. Exacerbations were classified according to Anthonisen criteria to determine the severity of exacerbation on admission. Severity of COPD was scored using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. For comparative analysis, severity of disease (GOLD criteria), age, sex and smoking history were matched.RESULTS: Of 109 admissions reviewed, 66 were single admissions (61%) and 43 were readmissions (39%). The number of readmissions ranged from two to nine (mean of 3.3 readmissions). More than 85% of admissions had the severity of COPD equal to or greater than GOLD stage 3. The significant indicators for readmission were GOLD status (P<0.001), number of related comorbidities (OR 1.47, 95% CI 1.10 to 1.97; P<0.009) and marital status (single) (OR 4.18, 95% CI 1.03 to 17.02; P<0.046). The requirement for social work involvement during hospital admission was associated with a prolonged LOS (P<0.05).CONCLUSIONS: The results of the present study show that disease severity (GOLD status) and number of comorbidities are associated with readmission rates of patients with AECOPD. Interestingly, social factors such as marital status and the need for social work intervention are also linked to readmission rates and LOS, respectively, in patients with AECOPD.

Optimal glucocorticoid dose and the effects on mortality, length of stay, and readmission rates in patients diagnosed with acute exacerbation of chronic obstructive pulmonary disease (AECOPD)

2019 ◽  
Vol 67 (8) ◽  
pp. 1161-1164
Author(s):  
Asim Kichloo ◽  
Michael Aljadah ◽  
Navya Vipparla ◽  
Farah Wani
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Acute Exacerbation ◽  
Low Dose ◽  
Future Research ◽  
Chronic Obstructive ◽  
High Dose ◽  
Readmission Rates ◽  
Glucocorticoid Treatment ◽  
Obstructive Pulmonary Disease

The burden of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is staggering on a national and global level. Yet, surprisingly, there is a profound lack of treatment standardization with glucocorticoids in the treatment of AECOPD. In this review, we bring attention to specific literature that use a cut-off of 60 mg prednisone equivalent per day when distinguishing between high-dose and low-dose glucocorticoid treatment. We hope this review encourages future research to begin incrementally lowering the cut-off dose of 60 mg to discover if mortality, length of hospital stays, and readmission rates change between high-dose and low-dose glucocorticoid treatment. The final hope would be to establish an optimal glucocorticoid dose to treat AECOPD and eliminate treatment ambiguity.

Sign in / Sign up

Export Citation Format

Share Document